Name: | rizatriptan |
---|---|
PubChem Compound ID: | 5078 |
Molecular formula: | C15H19N5 |
Molecular weight: | 269.345 g/mol |
Synonyms: |
N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine; 144034-80-0; 1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-; Rizatriptan; MK 462 free base; Risatriptan
|
Name: | rizatriptan |
---|---|
Name (isomeric): | DB00953 |
Drug Type: | small molecule |
Synonyms: |
Rizatriptan benzoate; Rizatriptan benzoat; MK 462 Free Base; Risatriptan
|
Brand: | Maxalt MLT, Maxalt, Maxalt-MLT |
Category: | Serotonin Agonists, Selective Serotonin Agonists, Vasoconstrictor Agents, Anti-migraine Agents, Anti-inflammatory Agents |
CAS number: | 145202-66-0 |
Indication: | For treatment of acute migraine attacks with or without aura. |
---|---|
Pharmacology: |
Rizatriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists and has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological act...
show more » |
Mechanism of Action: |
Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstricti...
show more » |
Absorption: | Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack. |
Protein binding: | 14% |
Biotransformation: | Rizatriptan is metabolized by monoamine oxidase A isoenzyme (MAO-A) to an inactive indole acetic acid metabolite. In addition, several other inactive metabolites are formed. An active metabolite, N-monodesmethyl-rizatriptan, with pharmacological activity similar to that of the parent compound has been identified in small concentrations (14%) in the plasma. |
Route of elimination: | Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism. |
Half Life: | 2-3 hours |
Toxicity: | Symptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|